Abiraterone + prednisone with ADT
Checked 2026-09-09
High-risk metastatic hormone-sensitive (LATITUDE, STAMPEDE) or castration-resistant prostate cancer
One cycle
every 28 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Abiraterone acetate Small-molecule CYP17A1 inhibitor | 1,000 mg once daily on an empty stomach | Oral | D1-28 | |
Prednisone | 5 mg once daily (twice daily in castration-resistant disease) | Oral | D1-28 | |
GnRH agonist or antagonist GnRH agonist depot | per depot schedule | SC | D1 |
Cycles
until progression
28-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Food increases exposure up to tenfold; take at least 1 hour before or 2 hours after a meal.
- Monitor potassium, blood pressure and liver enzymes; hypokalaemia and hypertension are mineralocorticoid effects.
Used in
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Docetaxel + prednisone
Metastatic hormone-sensitive (with ADT, 6 cycles: CHAARTED, ARASENS) or castration-resistant prostate cancer
every 21 days × 6
Cabazitaxel + prednisone
Metastatic castration-resistant prostate cancer after docetaxel and an AR-pathway inhibitor
every 21 days
177Lu-PSMA-617
PSMA PET-positive metastatic castration-resistant prostate cancer after an AR-pathway inhibitor (PSMAfore) and, in VISION, after taxane
every 42 days × 6
Olaparib maintenance
Newly diagnosed BRCA-mutant advanced ovarian cancer after platinum response (2 years); recurrent platinum-sensitive disease; BRCA/HRR-mutant prostate; germline BRCA pancreatic after platinum
every 28 days × 2